Hepcidin — Indexed Studies

Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: The UFA-Preserved2 Randomized Controlled Crossover Study.

Carbone S, Billingsley HE, Ahmed SI et al.

The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review.

Alebna PL, Martey S, Mehta A et al.

Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.

Sillassen CDB, Faltermeier P, Petersen JJ et al.

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

Verma S, Böttcher M, Brown P et al.

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Garvey WT, Blüher M, Osorto Contreras CK et al.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Davies MJ, Bajaj HS, Broholm C et al.

Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.

Gabe MBN, Fuhr R, Sinn A et al.

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Mann JFE, Rossing P, Bakris G et al.

Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices.

daSilva-deAbreu A, Rodgers JE, Seltz J et al.

Outcomes of Patients With Left Ventricular Assist Devices Requiring Intermittent Hemodialysis: Single-Center Cohort, Systematic Review, and Individual-Participant Data Meta-Analysis.

daSilva-deAbreu A, Faaborg-Andersen C, Joury A et al.

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Frias JP, Deenadayalan S, Erichsen L et al.

Challenges in Cardiovascular Evaluation and Management of Obese Patients: JACC State-of-the-Art Review.

Bianchettin RG, Lavie CJ, Lopez-Jimenez F

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Ahmed M, Hassan M, Tahir M et al.

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.

Cho YK, Jung CH

Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.

Al-Harbi FA, Alsaif AK, Almutairi AG et al.

Obesity paradox in coronary heart disease.

Lavie CJ, Catalfamo V, Carbone S

Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y(2) receptor tri-agonist for obesity and type 2 diabetes.

Liu X, Gong B, Wang T et al.

CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.

Jacobsen JM, Halling JF, Blom I et al.

Advancing Diabetes Management and Glycemic Control While Exploring CagriSema's Impact on Obesity Management.

Hadid S, Frishman WH, Aronow WS

Weight changes in obesity: the obesity paradox revisited.

Carbone S, Lavie CJ, Neeland IJ

Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks.

Furberg JF, Andersen PK, Scheike T et al.

Recent advances in peptide-based therapies for obesity and type 2 diabetes.

Bailey CJ, Flatt PR, Conlon JM

CagriSema and the link between obesity and type 2 diabetes.

Apovian CM, McDonnell ME

New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.

Pardali EC, Gkouskou KK, Cholevas C et al.

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

Gadelmawla AF, Hammad N, Atta K et al.

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Bailey CJ, Flatt PR, Conlon JM

Improving National Fitness: An Updated Review on Cardiovascular Disease Risk Screening and Exercise Training in School-Aged Children in the U.S.

Mendoza MF, Anzelmo MA, Suan NM et al.

The story of amylin: from physiology to therapy.

Secher A, Lutz TA, Raun K

A Growing Burden: Obesity's Impact on Cardiometabolic Disease Risk in Children and Adolescents.

Catalfamo VJ, Farhud S, Mulkey J et al.

Bariatric Surgery in the Era of GLP1RA: A Narrative Review.

Muhundan M, Dash S

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.

Abdelrahman RM, Musa TH, Arbab IA et al.

Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

Muskiet MHA, Nardone M, Rensen PCN et al.

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Son JW, le Roux CW, Blüher M et al.

Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.

Bhat S, Fernandez CJ, Lakshmi V et al.

Weight management treatment in obesity.

Rubio-Herrera MA, Mera-Carreiro S

Incretin-based therapies for the treatment of obesity-related diseases.

Caruso I, Cignarelli A, Sorice GP et al.

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.

Volčanšek Š, Koceva A, Jensterle M et al.

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Bailey CJ, Flatt PR, Conlon JM

Emerging pharmacotherapies for obesity: A systematic review.

Kokkorakis M, Chakhtoura M, Rhayem C et al.

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Dutta D, Nagendra L, Harish BG et al.

Central nervous system pathways targeted by amylin in the regulation of food intake.

Hankir MK, Le Foll C

Healthy Lifestyle and Cardiac Rehabilitation for Weight Loss.

Höchsmann C, Dorling JL, Lavie CJ et al.

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

Gogineni P, Melson E, Papamargaritis D et al.

What is the pipeline for future medications for obesity?

Melson E, Ashraf U, Papamargaritis D et al.

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Le Roux C, Mondoh A

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

Yao H, Zhang A, Li D et al.

Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.

Al-Horani RA, Aliter KF, Aliter HF

Update on obesity, the obesity paradox, and obesity management in heart failure.

Alebna PL, Mehta A, Yehya A et al.

Polyagonists in Type 2 Diabetes Management.

Dissanayake HA, Somasundaram NP